Analysed SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) News Sources
Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy
14-09-2026
advfn.com
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says
14-09-2026
yahoo.com
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
15-09-2026
yahoo.com
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
17-09-2026
yahoo.com
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
18-09-2026
biopharmadive.com
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
25-09-2026
yahoo.com
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
08-10-2026
yahoo.com
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)
16-10-2026
yahoo.com
What is the current price of SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ)?
The current price of SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) is $41.71.
SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) absolute price change since previous trading day?
The absolute price change of SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) since the previous trading day is $0.22.
SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) percentage price change since previous trading day?
The percentage price change of SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) since the previous trading day is 0.5302%.
What is the most recent average sentiment score for SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ)?
The most recent average sentiment score for SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ)?
The most recent sentiment for SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ) is .
SEC-8K** Filing Available For SCHOLAR ROCK HOLDING CORP (SRRK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.